VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as Chief Financial Officer and Head of Business Development, effective immediately. Mr. McNulty is an accomplished financial executive in the biopharmaceutical and medical device...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston, MA, on Wednesday,...
Read More
Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 Positive safety and immunogenicity data from Phase 1 study of VBI-1501 for Congenital Cytomegalovirus (CMV) reported in May 2018 Initial data from...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company will participate in the Oppenheimer Boston Oncology Insight Summit July 10 – 11, 2018. The two-day summit will...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on May 24, 2018 (the "Meeting"). The...
Read More
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest dose Safe and well-tolerated at all doses with no safety signals observed Conference call and webcast today, Thursday, May 10, 2018, at 8:30 AM...
Read More
Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of Congenital Cytomegalovirus (CMV) and VBI-1901 for the treatment of glioblastoma (GBM) VBI Vaccines...
Read More
More than 1,600 subjects enrolled in PROTECT study Topline data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) today announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of...
Read More
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More